<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272609</url>
  </required_header>
  <id_info>
    <org_study_id>10-PP-11</org_study_id>
    <secondary_id>2010-022440-20</secondary_id>
    <nct_id>NCT01272609</nct_id>
  </id_info>
  <brief_title>Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel</brief_title>
  <official_title>Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulsed dye laser (PDL)is the gold standard treatment of port wine stains (PWS). However, many
      sessions are required and failure or relapses are not uncommon. It has been demonstrated that
      a neoangiogenesis occurs after PDL, explaining at least partially those failure. The
      objective of this study is to evaluate the use of a topical beta-blocker (timolol 1% gel) as
      a combination treatment with PDL for treating PWS.

      Methods. Prospective multicenter study comparing PDL alone to PDL + timolol. Sessions of PDL
      will be performed once a month for 3 months. One group will be treated with PDL alone and the
      other will also applied timolol 1% gel twice a day during treatment. The evaluation will be
      done one month after the third session.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA</measure>
    <time_frame>one month after the third session</time_frame>
    <description>IGA (investigator global assessment) at 3 or 4 marked improvement or complete clearance one month after the third session. Blinded evaluation by two physicians on standardized photos
Colorimetric analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of the patients on visual analogical scale</measure>
    <time_frame>three months</time_frame>
    <description>Subjective evaluation of the patients on visual analogical scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>LCP + Timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol + LCP</intervention_name>
    <description>Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².</description>
    <arm_group_label>LCP + Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LCP</intervention_name>
    <description>Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.</description>
    <arm_group_label>LCP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children from 6 months to 18 year-old.

          -  PWS of the face

          -  No prior treatement with PDL

          -  Membership or beneficiary of a national insurance scheme.

          -  Consent signed by the parents and by the patient if he is old enough to understand

        Exclusion Criteria:

          -  Child with whom the angioma plan was already handled by laser or pulsed lamp

          -  Histories of asthma or obstructive bronchitis

          -  severe allergic Rhinitis and hyper bronchial ability to react

          -  Bradycardie sinusale, block auriculo-ventriculaires of the second or third degree

          -  unchecked Cardiac insufficiency

          -  cardiogenic Shock

          -  untreated Phéochromocytome

          -  Sentimentality in the timolol or in one of these excipients, and\or in the other
             bétabloquants

          -  Taken by floctafénine or by sultopride

          -  Taken of bétabloquants by oral route, of inhibitors calcic or of amiodarone

          -  severe peripheral circulatory Disorders(Confusions of Raynaud)

          -  arterial Low blood pressure

          -  Pregnancy and feeding

          -  Absence of effective contraception at the girls old enough to procreate

          -  Contraindication in the use of cream with lidocaïne and with prilocaïne
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PASSERON Thierry, Pu-Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice - Service de Dermatologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PASSERON Thierry, PU-PH</last_name>
    <phone>+33492039224</phone>
    <email>passeron.t@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nice - 4 avenue Reine Victoria</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PASSERON Thierry, PU-PH</last_name>
      <phone>+33492039224</phone>
      <email>passeron.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Passeron Thierry, Pu-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Labreze Christine, pu-ph</last_name>
      <email>'christine.labreze@chu-bordeaux.fr'</email>
    </contact>
    <investigator>
      <last_name>Labreze Christine, pu-ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sévigné</name>
      <address>
        <city>Cesson Sévigné</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toubel Gérard, Phd</last_name>
      <email>'gerard.toubel@wanadoo.fr'</email>
    </contact>
    <investigator>
      <last_name>TOUBEL Gérard, phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vabres Pierre, PhD</last_name>
      <email>pierre.vabres@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Vabres Pierre, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Turin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazer Jean-Marc, Phd</last_name>
      <email>'jmmazer@wanadoo.fr'</email>
    </contact>
    <investigator>
      <last_name>Mazer Jean-Marc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Quimper</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plantin Patrick, phd</last_name>
      <email>'p.plantin@ch-cornouaille.fr'</email>
    </contact>
    <investigator>
      <last_name>Plantin Patrick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ESCHARD Christine, Pu-Ph</last_name>
      <email>'ceschard.chu-reims@medical51.apicrypt.org'</email>
    </contact>
    <investigator>
      <last_name>Eschard Christine, Pu-Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mathilde</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossi Bernard, PHD</last_name>
      <email>'bernard.rossi@clinique-clinique.orange.fr'</email>
    </contact>
    <investigator>
      <last_name>Rossi bernard, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Touloluse</name>
      <address>
        <city>Toulouse</city>
        <zip>31 0000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAZEREEUW juliette, Pu-Ph</last_name>
      <email>'mazereeuw-hautier.j@chu-toulouse.fr'</email>
    </contact>
    <investigator>
      <last_name>MAZEREEUW juliette, Pu-Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-jean Languedoc</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dahan serge, phd</last_name>
      <email>'dahan.serge@wanadoo.fr'</email>
    </contact>
    <investigator>
      <last_name>Dahan Serge, phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Port-Wine Stain</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

